top of page

CIPLA - MUCINAC+ (NOW AB)

Background: CIPLA, a global pharmaceutical leader, sought to enhance its product line with Mucinac+ (now AB), an advanced version of its well-established Mucinac. Mucinac+ (now AB) incorporates two additional molecules that not only prevent chronic obstructive pulmonary disorder (COPD) but also aid in opening the air passages, making it easier to breathe. The product effectively relieves symptoms such as coughing, wheezing, and shortness of breath. Our team was commissioned to design a Brand and Communication strategy that would leverage the existing Mucinac identity while emphasizing the enhanced benefits of Mucinac+ (now AB).

Objectives: The primary objectives of the campaign were:

  1. Brand Consistency: Ensure that the new product aligns with the existing Mucinac brand identity while highlighting its unique features.

  2. Awareness: Increase public awareness of Mucinac+ (now AB) and its benefits.

  3. Engagement: Engage healthcare professionals, patients, and key stakeholders to build trust and credibility.

  4. Adoption: Drive adoption of Mucinac+ (now AB) among patients and healthcare providers.

Strategy: Our strategy was designed to create a seamless integration of Mucinac+ (now AB) into the existing Mucinac brand while emphasizing its additional benefits. Key elements of the strategy included:​​

  1. Brand Identity:

    • Developed a cohesive brand identity for Mucinac+ (now AB) that incorporated the existing Mucinac orange color scheme.

    • Designed a distinct logo and visual elements that highlighted the product's enhanced features.

  2. Content Marketing:

    • Created informative and engaging content, including blog posts, articles, and social media updates, that explained the benefits of Mucinac+ (now AB).

    • Collaborated with healthcare experts to produce educational videos and webinars.

  3. Social Media Campaign:

    • Launched targeted social media campaigns on platforms like Facebook, Twitter, and Instagram to reach a broad audience.

    • Utilized testimonials from patients and healthcare professionals to build trust and credibility.

  4. Community Outreach:

    • Organized health awareness programs and seminars in collaboration with local healthcare providers and organizations.

    • Conducted awareness sessions in hospitals, clinics, and community centers.

SERVICES

Identity, Packaging, Inclinic Engagement, Digital 

CIPLA LOGO.gif

IDENTITY

The campaign was executed in three phases:

  1. Phase 1: Pre-launch (Awareness and Teaser Campaign)

    • Built anticipation through teaser campaigns on social media and outdoor advertising.

    • Released informative content to prime the audience for the upcoming product launch.

  2. Phase 2: Launch (Main Campaign)

    • Unveiled the official campaign with a press conference and media event.

    • Rolled out the full suite of marketing materials and content across all channels.

  3. Phase 3: Post-launch (Sustained Engagement and Follow-up)

    • Continued to engage the audience with regular updates, success stories, and follow-up campaigns.

    • Monitored campaign performance and made data-driven adjustments to optimize results.

Mucinac+_Medical_Pack

PACKAGING

Mucinac+_LBL_With_Folder_Cover
Mucinac+_LBL_With_Folder_Inside

LEAVE BEHIND LEAFLET WITH COVER

Mucinac+_Teaser_Sleeve_with_Bi-fold_Leaf

TEASER (SLEEVE WITH BI-FOLD LEAFLET)

Mucinac+_Visual_Aid_Cover
Mucinac+_Visual_Aid_Inside

VISUAL AID

IN-CLINIC ENGAGEMENT 

Mucinac+_In-Clinic_Engagement_(Video_Display_Easel)
Mucinac+_Whatsapp_Teaser

IN-CLINIC ENGAGEMENT (VIDEO DISPLAY EASEL)​​

WHATSAPP COMMUNICATION

RESULTS

The campaign achieved significant success, with key outcomes including:

  • Brand Consistency: Successfully integrated Mucinac+ (now AB) into the existing Mucinac brand identity.

  • Awareness: Increased public awareness of Mucinac+ (now AB) by 60%.

  • Engagement: Engaged over 300,000 individuals through social media, community outreach, and awareness programs.

  • Adoption: Achieved a 40% increase in the adoption of Mucinac+ (now AB) among patients and healthcare providers within the first six months of the campaign.

Conclusion:

The Brand and Communication Design for CIPLA's Mucinac+ (now AB) showcased the importance of maintaining brand consistency while highlighting the enhanced benefits of a new product. The campaign effectively raised awareness, engaged key stakeholders, and drove adoption, contributing to improved respiratory health outcomes.

MERCHANDISE FOR THE SEROFLO DEVICE

Our goal was to develop merchandise items that replicate the shape of the Seroflo inhaler. These items can be presented to doctors, ensuring they keep the product top-of-mind and are more likely to recommend it. 

Cipla - Seroflo Table Clock.jpg
Cipla - Seroflo Air-Freshner.jpg
Cipla - Seroflo Pen Stand.jpg
santizer-mockup.jpg
Cipla - Seroflo Paperweight.jpg
Cipla - Seroflo Unipower Adapter_1.jpg
Cipla - Seroflo Unipower Adapter_2.jpg
Cipla - Seroflo Unipower Adapter_3.jpg

MERCHANDISE

  • LinkedIn
  • Instagram
WHATSAPP ICON.png

© Copyright Pavan Java Studio No material or information from this presentation may be copied, reproduced, republished, uploaded, posted, transmitted or distributed except as authorized in the terms of use, expressly authorized/approved in writing by Imperial Graphics Studio.

bottom of page